Capricor Therapeutics Inc
NASDAQ:CAPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Enento Group Oyj
OMXH:ENENTO
|
FI |
|
E
|
eWeLL Co Ltd
TSE:5038
|
JP |
Capricor Therapeutics Inc
EPS (Diluted)
Capricor Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
EPS (Diluted)
-$2
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
EPS (Diluted)
-$1
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Capricor Therapeutics Inc
Glance View
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.
See Also
What is Capricor Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-2.3
USD
Based on the financial report for Dec 31, 2025, Capricor Therapeutics Inc's EPS (Diluted) amounts to -2.3 USD.
What is Capricor Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
12%
Over the last year, the EPS (Diluted) growth was -97%. The average annual EPS (Diluted) growth rates for Capricor Therapeutics Inc have been -24% over the past three years , -21% over the past five years , and 12% over the past ten years .
